Ferrin Marianne, Zuckerman Jonathan B, Meagher Alison, Blumberg Emily A
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Pediatr Pulmonol. 2002 Mar;33(3):221-3. doi: 10.1002/ppul.10062.
Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of pulmonary infection in patients with cystic fibrosis (CF). Because these organisms are frequently multidrug-resistant, most patients require intravenous therapy with vancomycin. We report on the first case of successful treatment of a pulmonary exacerbation due to MRSA in a CF patient with a new antimicrobial, linezolid. We demonstrated equivalence of intravenous and oral dosing in this patient, suggesting that oral linezolid may be an excellent alternative to intravenous vancomycin for CF patients infected with MRSA.
耐甲氧西林金黄色葡萄球菌（MRSA）是囊性纤维化（CF）患者肺部感染的重要原因。由于这些病原体常常具有多重耐药性，大多数患者需要用万古霉素进行静脉治疗。我们报告了首例使用新型抗菌药物利奈唑胺成功治疗一名CF患者因MRSA导致的肺部病情加重的病例。我们证明了该患者静脉给药和口服给药的等效性，这表明对于感染MRSA的CF患者，口服利奈唑胺可能是静脉用万古霉素的极佳替代药物。
